Myosana Therapeutics

Executive Summary

Myosana Therapeutics is a San Diego-based biotech pioneering a non-viral gene therapy platform for neuromuscular and cardiac diseases, with initial focus on Duchenne muscular dystrophy (DMD) and X-linked myotubular myopathy (MTM). Founded in 2019, the company aims to overcome the safety and efficacy limitations of viral vectors by leveraging proprietary non-viral delivery technology. This approach could enable repeat dosing and reduce immunogenicity, potentially broadening treatable patient populations. Myosana is privately held with no disclosed funding or valuation, and its profile suggests it is at a preclinical stage. The non-viral gene therapy space is competitive, but Myosana's specialization in neuromuscular indications offers a differentiated niche. Key near-term risks include technical challenges in delivery efficiency and manufacturing scalability, as well as competition from established viral gene therapy programs. Despite limited public information, the platform's potential to address critical unmet needs warrants monitoring. The conviction score of 55 reflects early-stage uncertainty balanced by the novelty of the approach.

Upcoming Catalysts (preview)

• Q3 2026Lead Candidate Preclinical Data Release60% success
• Q4 2026Series A Financing Announcement50% success
• H1 2027IND Filing for DMD Program40% success